

## REFERENCES

- Adamkiewicz TV, Lorenzana A and Doyle J (1999):*** Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. *Pediatr Infect Dis J*; 18: 556-8.
- American Academy of Pediatrics (2000):*** Immunizations in special clinical circumstances. In: Pickering LK (ed.) *Red Book: report of the committee on Infectious Diseases*, 25<sup>th</sup> ed. Elk Grove Village: American Academy of Pediatrics: 56-68.
- Ammann RA, Hirt A, Luthy AR and Aebi C (2004):*** Predicting bacteraemia in children with fever and chemotherapy-induced neutropenia. *Pediatr Infect Dis J* 23, pp. 61-67.
- Anderson W (1999):*** Immunology In: Fence Creek: Microbiology and immunology, 1<sup>st</sup> edition. Madison, Connecticut: 46-50.
- Baron EJM, Weinstein MP, Dunne WM Jr, Yagupsky P, Welch DF and Wilson DM (2005):*** *Cumitech 1C, Blood Cultures IV*. Washington, DC: American Society for Microbiology.
- Basu SK, Fernandez ID, Fisher SG, Asselin BL and Lyman GH (2005):*** Length of stay and mortality associated with febrile neutropenia among children with cancer. *J Clin Oncol* 23, pp. 7958-7966.
- Bodey GP, Buckley M, Sathe YS et al., (1966):*** Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966; 64:328-340.

- Boogaerts M, Winston DJ and Bow EJ (2001):** Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. *Ann Intern Med*; 135: 412-22.
- Boragina M, Patel H, Reiter S and Dougherty G (2007):** Management of febrile neutropenia in paediatric oncology patients: a Canadian survey. *Pediatr Blood Cancer* 48, pp. 521-526.
- Bow EJ, Laverdiere M and Rotstein C (2000):** A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical antifungal therapy in persistently febrile neutropenic patients despite broad-spectrum antibacterial therapy In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington D.C. American Society for Microbiology; 112-119.
- Bow EJ, Laverdiere M, Lussier N and Rotstein C (1999):** Antifungal prophylaxis in neutropenic patients: a meta-analysis of randomized-controlled trials. *Blood*; 94 (Suppl 1): 339A.
- Chan WC, Li RC, Ling JM, Cheng AF and Schentag JJ (1999):** Antimicrob Chemother; Jan 43(1): 55-60.
- Charnas R, Luthi AR and Ruch W (1997):** Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. *Pediatr Infect Dis J*; 16: 346-53.

- Chatzinikalaou I, Abi-Said D and Bodey GP (2000):*** Recent experience with *Pseudomonas aeruginosa* bacteremia in patients with cancer: retrospective analysis of 245 episodes. *Arch Intern Med*; 160: 501-9.
- Corapcioglu F and Sarper N (2005):*** Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. *Pediatr Hematol Oncol*
- Corapcioglu F, Sarper N and Zengin E (2006):*** Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in paediatric cancer patients: a randomized comparison. *Pediatr Hematol Oncol* 23, pp. 177-186.
- De Cueto M, Ceballos E, Martinez-Martinez L, Perea EJ and Pascual A (2004):*** Use of positive blood cultures for direct identification and susceptibility testing with the Vitek 2 system. *J Clin Microbiol* 42, 3734–3738
- Del Favero A, Menichetti F and Martino P (2001):*** A multicenter, double blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. *Clin Infect Dis*; 33: 1295-301.
- Donowitz GR, Maki DG, Crnich CJ, Pappas PG and Rolston KV (2001):*** Infections in the neutropenic patient-new views of an old problem. *Hematology Am Soc Hematol Educ Program* pp.
- El-Attar I (2002):*** Biostatistics and epidemiology. *Cancer registration NCI Egp; Mach Vol* 10: 39-45.

- El-Mahallawy H, Mohamed NH, Attia EA and Moneeb N (1999):*** Risk factor evaluation and prognosis of bacteremia in children with cancer. J Egy NCI Sep; Vol 11: no 3.
- Elting LS, Rubenstein EB and Rolston K (2000):*** Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol; 18: 3699-706.
- Fanci R, Paci C, Leoni F, Casini C and Longo G (2003):*** Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial. J Chemother.
- Feld R (1999):*** Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis; 29: 503-7.
- Feld R, DePauw B and Berman S (2000):*** Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol; 18: 3690-8.
- Fiser RT, West NK, Bush AJ et al., (2005):*** Outcome of severe sepsis in pediatric oncology patients. Pediatr Crit Care Med 2005; 6:531-536.
- Freifeld A, Marchigiani D and Walsh T (1999):*** A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med; 341: 305-11.
- Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F and Terenziani M (2005):*** Childhood cancer survival trends in Europe: a EURO CARE Working Group study. J Clin Oncol 23, pp. 3742-3751.

**Gencer S, Salepci T and Ozer S (2003):** Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. *J Infect.* pp. 65-72.

**Gomez L, Garau J, Estrada C, Marquez M, Dalmau D and Zercavins M (2003):** Ciprofloxacin prophylaxis in patients with acute leukaemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant *Escherichia coli*. *Cancer.*

**Greenberg D, Moser A, Yagupsky P et al., (2005):** Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in pediatric febrile neutropenic oncology patients: Comparison between two consecutive time periods with use of different antibiotic treatment protocols. *Int J Antimicro Agents* 2005; 25:469-473.

**Hallahan AR, Shaw PJ, Rowell G et al., (2000):** Improved outcomes of children with malignancy admitted to pediatric intensive care unit. *Crit Care Med* 2000; 28: 3718-3721.

**Hann I, Viscoli C, Paesmann M et al., (1997):** A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. *Br J Haematol* 1997; 99:580-588.

**Hemsworth S, Nunn AJ, Selwood K, Osborne C, Jones A and Pizer B (2005):** Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. *Acta Paediatr* 94, pp. 268-274.

**Hubel K, Dale DC, Engert A and Liles WC (2001):** Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. *J Infect Dis*; 183: 321-8.

- Hughes WT, Armstrong D, Bodey GP et al., (2002):** Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751.
- Jennifer A, Margarte S et al., (2008):** Outcome of gram negative infection in immunocompromised children.
- Jitsurong S and Yodsawat J (2006):** Prevalence of extended-spectrum beta-lactamases (ESBLs) produced in blood isolates of gram-negative bacteria in a teaching hospital in southern Thailand. Southeast Asian J Trop Med Public Health.
- Junquera S, Loza E and Baquero F (2005):** Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections. Enferm Infecc Microbiol Clin.
- Kanamaru A and Tatsumi Y (2004):** Microbiological data for patients with febrile neutropenic, Clin Infect Dis 2004; 39:37-510.
- Klaasseen RJ, Goodman R, Pham BA and Doyle JJ (2000):** "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol; 18: 1012-19.
- Klastersky J, Paesmans M and Rubenstein EB (2000):** The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol; 18:3038-51.

- Lan CK, Hsueh PR and Wong WW (2003):** Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. *J Microbiol Immunol Infect.*
- Marr KA, Seidel K and White TC (2000):** Candidemia in allogenic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. *J Infect Dis*; 181: 309-16.
- McDonald LC, Weinstein MP and Mirrett S (2001):** Controlled comparison of BacT/ALERT FAN aerobic medium and VATEC fungal blood culture medium for detection of fungemia. *J Clin Microbiol*; 39: 622-4.
- Mermel LA, Farr BM and Sheretz RJ (2001):** Guidelines for the management of intravascular catheter related infection. *Clin Infect Dis*; 32: 1249-72.
- Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ and Kollef MH (2005):** *Pseudomonas aeruginosa* bloodstream infection: importance of appropriate initial antimicrobial treatment. *Antimicrob Agents Chemother* 49, 1306-1311.
- Morbidity and Mortality Weekly Report (2000):** Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients recommendations of CDC (Centers for Disease Control and Prevention). The Infectious Diseases Society of America and the American Society of Blood and Transplantation; 49 (RR-10): 1-125.
- Murray PR (1999):** Immunology In: Murray PR. (eds.): Manual of Clinical Microbiology 7th edition, ASM press; 542.

- Nucci M, Biasoli I and Akiti T (2000):** A double blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. *Clin Infect Dis*; 30: 300-5.
- Owens RC, Owens CA and Holloway WJ (2000):** Reduction in vancomycin consumption in patients with fever and neutropenia. *Clin Infect Dis*; 31: 291.
- Ozer H, Armitage JO and Bennett CL (2000):** Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. *J Clin Oncol*; 18: 3558-85.
- Paganini HR, Sarkis CM and DeMartino MG (2000):** Oral administration of cefixime to lower risk febrile neutropenic children with cancer. *Cancer*; 88: 2848-52.
- Parkin DM, Stiller CA and Draper GJ (1988):** International incidence of childhood cancer. IARC scientific publication No. 87. Lyon: International Agency for Research on Cancer Scientific Publication.
- Paterson DL, Ko WC and Von Gottberg A (2004):** International prospective study of *Klebsiella pneumoniae* bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. *Ann Intern Med*.
- Paul M, Yahav D, Fraser A and Leibovici L (2006):** Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 57, pp. 176-189.



- Peacock JE, Wade JC and Lazarus HM (1997):** Ciprofloxacin/piperacillin vs. tobramycin/piperacillin as empiric therapy for fever in neutropenic cancer patients, a randomized, double-blind trial In: Program and abstracts of the 37<sup>th</sup> Interscience Conference on Antimicrob Agents and Chemotherapy (Toronto). Washington DC: American Society for Microbiology.
- Perry MC and Yarbaro JW (1984):** Toxicity of chemotherapy In: Orlando, Grune and Stratton (eds.): Pharmacokinetics of Chemotherapy, Lippincott Co; 268.
- Phillips B, Selwood K, Lane S, Skinner R, Gibson F and Chisholm JC (2007):** Variation in policies for the management of febrile neutropenia in the United Kingdom Children's Cancer Study Group Centers. Arch Dis Child 92, pp. 495-498.
- Phillips R, Skinner R and Chisholm JC (2007):** Treating low-risk febrile neutropenia: Jenny's story. Arch Dis Child 92, pp. 7-8.
- Pickering LK, Anderson DC and Choi S (1975):** Leukocyte function in children with malignancy. Cancer; 35:1365.
- Pizzo PA (1989):** Consideration for the prevention of infectious complications in patients with cancer. Rev Infect Dis; 11: 1551.
- Pizzo PA and Poplack DG (2008):** Principles and practice of pediatric oncology. Philadelphia, JB Lippincott; 543.
- Pizzo PA, Ladisch S and Robichaud K (2003):** Treatment of gram-positive septicemia in cancer patients. Cancer; 45:206-7.

- Pizzo PA, Robichaud KJ, Gill FA and Witebsky FG (1982):** Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. *Am J Med*; 72: 101-11.
- Raad II, Vartivarian S and Khan A (1991):** Catheter-related infections caused by the *Mycobacterium fortuitum* complex: 15 cases and review. *Rev Infect Dis*; 13: 1120-5.
- Ramzi J, Mohamed Z, Yosr B et al., (2007):** Predictive factors of septic shock and mortality in neutropenic patients, Department of Hematology Place du gouvernement la Kasbah, Aziza Othmana University Hospital, Tunis, Tunisia hematology *Onc J* 2007.
- Ramphal R (1999):** Is monotherapy for febrile neutropenia still a viable alternative? *Clin Infect Dis*; 29: 508-14.
- Ries LAG, Hankey BF and Edwards BK (1997):** Cancer statistics review 1973-1987. The surveillance program division of cancer prevention and control. NIH publication no. 90-2789. cancer statistics. *CA Cancer J Clin*; 47: 1.
- Riikonen P (1991):** Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. *Pediatr Infect Dis J* Dec; 10(12): 918-23.
- Rolston KVI and Tarrand JJ (1999):** *Pseudomonas aeruginosa* still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. *Clin Infect Dis*; 29: 463-4.

**Rolston KVI, LaBlanc BM and Balakrishnan M (2000):** In-vitro activity of moxifloxacin against gram-negative isolates from cancer patients In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology.

**Rolston KVI. (1999):** New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis; 29: 515-21.

**Rolston RVI, Balakrishnan M and Elting LS (2000):** Is quantitative variation in cancer patients with bacteremic infections linked to severity of infection? In: Program and abstracts of the 40<sup>th</sup> Interscience Conference for Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology.

**Rolston RVI, Balakrishnan M and Elting LS (2000):** Is quantitative variation in cancer patients with bacteremic infections linked to severity of infection? In: Program and abstracts of the 40th Interscience Conference for Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology.

**Rosenman M, Madsen K and Hui S (2002):** Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol.

**Rotstein C, Bow EG and Laverdiere M (2000):** Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis; 28: 331-40.

- Rubinstein E, Cammarata SK and Oliphant TH (2001):** Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. *Clin Infect Dis*; 32: 402-12.
- Safdar N, Handelsman J and Maki DG (2004):** Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. *Lancet Infect Dis*.
- Sankila R, Martos Jimenez Mc, Miljus D et al., (2006):** geographical comparison of cancer survival in European children (1988-1997) *Eur J Cancer*; 42: 1972-1980.
- Schimpff S, Satterlee W, Young VM et al., (1971):** Empiric therapy with carbenacillin and gentamicin for febrile patients with cancer and granulocytopenia. *N Engl J Med* 1971; 284:1061-1066.
- Shenep JL, Flynn PM and Baker DK. (2001):** Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. *Clin Infect Dis*; 32: 36-43.
- Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM and Dybdahl B (2005):** A multicentre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. *Scand J Infect Dis* 37, pp. 455-464.
- Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G and Engelhart S (2006):** Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. *Int J Antimicrob Agents* 28, pp. 417-422.

- Simon A, Groger N, Wilkesmann A, Hasan C, Wiszniewsky G and Engelhart S (2006):** Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. *Int J Antimicrob Agents* 28, pp. 417-422.
- Torfoss D, Hoiby EA, Tangen JM, Holte H, Bo K and Meyer P (2007):** Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. *J Antimicrob Chemother* 59, pp. 711-717.
- Vandercam B, Gerain J and Humblet Y (2000):** Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic patients. *Ann Hematol*; 79: 152-7.
- Vignoli R, Calvelo E, Cordeiro NF, Lucero R, Ingold E and Quintana A (2006)** Association of broad-spectrum antibiotic use with faecal carriage of oxy-iminocephalosporin-resistant enterobacteriaceae in an intensive care unit. *J Hosp Infect* 63, pp. 306-315.
- Viscoli C, Bruzzi P, Castagnola E et al., (1994):** Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. *Eur J Cancer* 1994; 30:430-437.
- Viscoli C, Catagnola E, Giacchino M et al., (1999):** Bloodstream infections in children with cancer: A multicenter surveillance study of the Italian Association of Pediatric Hematology and Oncology. *Eur J Cancer* 1999; 35:770-774.

- Walsh TJ, Finberg RW and Arndt C (1999):** Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *N Engl J Med*; 340: 764-71.
- Wang FD, Liu CY and Hsu HC (1999):** A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. *Chemotherapy*; 45: 370-9.
- William M and Crist (2000):** Pediatric cancer In: Nelson: Pediatrics textbook, 16th edition; 958.
- Wingard JR, Merz WG and Rinaldi MG (1991):** Increase in *Candida krusei* infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. *N Engl J Med*; 325: 1274-7.
- Wingard JR, White MH and Anaissie E (2000):** A randomized, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin lipid complex in the empirical treatment of febrile neutropenia. *Clin Infect Dis*; 31: 1155-63.
- Winston DJ, Hathorn JW and Schuster MG (2000):** A multi-center randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. *Am J Med*; 108: 282-9.
- Winston DJ, Lazarus HM and Beveridge RA (2001):** Randomized, double blind multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. *Clin Infect Dis*; 32: 381-90.

- Woo PC, Wong SS and Lum PN (2001):** Cell-wall deficient bacteria and culture-negative febrile episodes in bone marrow recipients. *Lancet*; 357: 675-9.
- Wu P-S, Chans L-Y et al., (2006):** Outcome of sever sepsis in pediatric oncology patients 2006; 39:144-149.
- Yoshida M Karasawa M and Naruse T (2000):** Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. *Int J Hematol*; 69: 81- 8.
- Zinner Sh (1999):** Changing epidemiology of infections in patients with neutropenia and cancer. *Clin Infect Dis*; 29:490-494.